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Objectives The purpose of this study was to determine the prevalence, clinical significance, and genetic basis of hypertro-
phic cardiomyopathy (HCM) with “restrictive phenotype” characterized by restrictive filling and minimal or no left
ventricular hypertrophy.
Background Hypertrophic cardiomyopathy is a heterogeneous myocardial disorder with a broad spectrum of clinical presenta-
tion and morphologic features. Recent reports indicated that some patients with restrictive cardiomyopathy,
which is an uncommon condition defined by restrictive filling and reduced diastolic volumes with normal or near
normal left ventricular wall thickness and contractile function, have features suggestive of HCM with mutations
in cardiac troponin I, myocyte disarray at explant/autopsy, and relatives with HCM. Systematic evaluation of the
restrictive phenotype in HCM patients has not been performed.
Methods We evaluated 1,226 patients from 688 consecutive HCM families to identify individuals who fulfilled diagnostic
criteria for “restrictive phenotype.”
Results Nineteen of 1,226 affected individuals (1.5%) from 16 families (2.3%) had the “restrictive phenotype.” During
follow up (53.7  49.2 months), 17 patients (89%) experienced dyspnea (New York Heart Association functional
class 2). The 5-year survival rate from all-cause mortality, cardiac transplantation, or implantable cardioverter-
defibrillator discharge was 56.4%. Mutation analysis for 5 sarcomere genes was feasible in 15 of 16 probands.
Mutations were found in 8: 4 in beta-myosin heavy chain, and 4 in cardiac troponin I.
Conclusions The “restrictive phenotype” in isolation is an uncommon presentation of the clinical spectrum of HCM and is as-
sociated with severe limitation and poor prognosis. This phenotype may be associated with beta-myosin heavy
chain and cardiac troponin I mutations. (J Am Coll Cardiol 2007;49:2419–26) © 2007 by the American Col-
lege of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.02.061w
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(ypertrophic cardiomyopathy (HCM) is a familial myocar-
ial disorder caused by mutations in sarcomere protein
enes (1–3). Although the mechanisms are not clear, these
enetic alterations result in the characteristic pathological
myocyte disarray and fibrosis) and morphologic (hypertro-
hied, nondilated left ventricle) features of HCM (4).
See page 2427
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ingdom; †Department of Medicine and Geriatrics, Kochi Medical School, Kochi,
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ark. This study was supported by a grant from the British Heart Foundation.p
Manuscript received October 18, 2006; revised manuscript received February 1,
007, accepted February 5, 2007.Diastolic abnormalities occur in the majority of patients
ith HCM and have long been recognized as a determinant
f symptoms and exercise limitation (5–7). The diastolic
bnormalities seen in the majority of patients are mild and
onsist of impaired relaxation and slow left ventricular (LV)
lling, but some patients exhibit more severe diastolic
bnormalities with rapid early filling and restrictive physi-
logy. Recently, we reported a family with disease caused by
mutation in cardiac troponin I in which 12 individuals had
ypical HCM and 3 others exhibited a “restrictive pheno-
ype” characterized by restrictive filling and minimal or no
eft ventricular hypertrophy (LVH), which (if seen in
solation) resembled idiopathic restrictive cardiomyopathy
RCM) (8,9). In addition, there are reports of patients who
resent clinically with typical features of RCM and are
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HCM With Restrictive Phenotype June 26, 2007:2419–26found ultimately to have typical
histopathological findings of
HCM (10,11). Those patients
could be diagnosed with HCM
or RCM on another occasion.
Although the “restrictive pheno-
type” may be part of the clinical
spectrum of HCM, systematic
evaluation of this “restrictive
phenotype” in the context of
HCM patients has never been
performed. We focused on the
gray zone (minimal or no LVH
[maximum LV wall thickness
(MLVWT) 15 mm] and se-
vere diastolic dysfunction) be-
tween HCM and RCM where
diagnosis may be problematic.
The purpose of this study was
to determine the prevalence,
clinical characteristics, natural
history, and genetic basis of HCM
with “restrictive phenotype.”
Methods
Study population. We system-
atically evaluated 1,226 patients
with HCM from 688 families
who were evaluated in a dedi-
cated HCM clinic between 1988
and 2002. The diagnosis of HCM
was based on either of the follow-
ing criteria: 1) unexplained LVH
i.e., MLVWT 13 mm); or 2) unexplained electrocardio-
raphic and/or echocardiographic abnormalities in the context
f proven familial HCM with at least 1 relative who had an
nequivocal diagnosis with conventional clinical or his-
opathological diagnostic features.
Patients with other causes of LVH such as Friedreich’s
taxia, Noonan’s syndrome, and primary metabolic disor-
ers (e.g., Fabry disease, amyloidosis) were excluded.
linical evaluation. The evaluation of patients included
edical history; clinical examination; pedigree analysis;
2-lead electrocardiography (ECG); ambulatory 48-h
olter ECG analysis; M-mode, 2-dimensional, and Dopp-
er echocardiography; and maximal exercise testing with
etabolic gas exchange measurements and continuous as-
essment of blood pressure response.
Patients were classified as “restrictive phenotype” on
chocardiography if they fulfilled all of the following crite-
ia: minimal or no LVH (MLVWT 15 mm), transmitral
oppler indexes of restrictive filling (peak E-wave/A-wave
elocity ratio [E/A] 2 and deceleration time 150 ms),
ormal systolic function (fractional shortening [FS]25%),
Abbreviations
and Acronyms
CI  confidence interval
E/A  peak E-wave/
A-wave velocity ratio
FS  fractional shortening
HCM  hypertrophic
cardiomyopathy
ICD  implantable
cardioverter-defibrillator
LV  left ventricular
LVEDD  left ventricular
end-diastolic diameter
LVESD  left ventricular
end-systolic diameter
LVH  left ventricular
hypertrophy
MLVWT  maximum left
ventricular wall thickness
MYBPC3  cardiac myosin-
binding protein C gene
MYH7  beta-myosin heavy
chain gene
RCM  restrictive
cardiomyopathy
R-E  Romhilt-Estes
TNNI3  cardiac troponin I
gene
TNNT2  cardiac troponin
T gene
TPM1  alpha-tropomyosin
genend reduced or normal ventricular cavity size (left ventric- wlar end-diastolic diameter [LVEDD]  normal for age
nd body surface area) (12,13).
For survival analysis, 3 modes of HCM-related death
ere defined: 1) sudden and unexpected death (including
esuscitated cardiac arrest), in which collapse occurred in the
bsence of or 1 h from the onset of symptoms in patients
ho previously experienced a relatively stable or uneventful
linical course; 2) heart failure-related death, which was in
he context of progressive cardiac decompensation 1 year
efore death, particularly if complicated by pulmonary
dema or evolution to the end-stage phase (including
atients who had undergone heart transplantation); and 3)
troke-related death, which occurred as a result of probable
r proven embolic stroke. In patients with implantable
ardioverter-defibrillators (ICDs), the first appropriate
hock was coded as an outcome in a separate survival
nalysis.
Data on survival and clinical status were obtained from
atients with and without restrictive physiology during
erial clinic visits or by direct communication with patients
nd their cardiologists for patients who were followed up at
ther institutions.
Echocardiography was performed using an Acuson 128
P/10 (Mountain View, California), GE Vingmed system
(GE Ultrasound Europe, Horten, Norway) or a Hewlett-
ackard Sonos 1000 (Hewlett-Packard, Andover, Massa-
husetts). Standard views for 2-dimensional and M-mode
tudies were obtained. The severity and distribution of
VH were assessed in the parasternal short-axis plane at
itral valve and papillary muscle levels (14,15). Maximum
V wall thickness was defined as the greatest thickness in
ny single segment. Left ventricular end-diastolic diameter
nd left ventricular end-systolic diameter (LVESD) were
easured from M-mode and 2-dimensional images ob-
ained from parasternal long-axis views, and FS (FS 
00  [LVEDD  LVESD]/LVEDD) was calculated.
itral inflow velocities were determined using pulse-wave
oppler with the sample volume positioned at the tips of
he mitral leaflets in the 4-chamber view. Peak E-wave
elocity (E), peak A-wave velocity (A), E/A ratio, and
-wave deceleration time were recorded. Left ventricular
utflow tract gradient was calculated from continuous-wave
oppler using the simplified Bernoulli equation.
Patients underwent symptom-limited cardiopulmonary
xercise testing on a bicycle ergometer (Sensormedics Er-
ometrics 800S, Bitz, Germany) using an incremental ramp
rotocol with respiratory gas sampling (V Max 29 Console,
ensormedics) and serial measurement of blood pressure dur-
ng upright exercise. Peak oxygen consumption (VO2) was
efined as the highest VO2 achieved during exercise (16).
enetic analysis. In patients identified as having restric-
ive phenotype, systematic mutation analysis for recognized
CM-causing genes was performed. Informed consent was
btained in accordance with the guidelines of the local
nstitution’s review committee. Peripheral blood samples
ere taken at the time of clinical evaluation, and they were
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June 26, 2007:2419–26 HCM With Restrictive Phenotyperozen and stored at 20°C. DNA was extracted. In vitro
mplification of genomic DNA was performed using poly-
erase chain reaction. Sequencing was performed with a
ye-terminator cycle sequence system and analyzed as pre-
iously described (8). In patients in whom a mutation was
dentified, confirmation was obtained by reanalysis with
irect sequencing from a second blood sample.
Echocardiographic Characteristics of Patients a
Table 1 Echocardiographic Characteristics o
Patients W
“Restrictive Ph
(n  19
MLVWT, mm 13 2.7 (7–
Left atrial diameter, mm 53 4.5 (46
LV end-diastolic diameter, mm 45 4.7 (37
LV end-systolic diameter, mm 29 5.1 (20
Fractional shortening, % 37 6.4 (25
E/A 2.78 0.60 (2
DT, ms 115 24 (70
LVOTO, n (%) 0 (0%)
Data shown as mean  SD (range) or n (%). *Fisher exact test was us
DT  E-wave deceleration time; E/A  peak E-wave/A-wave velocit
left ventricular outflow tract obstruction 30 mm Hg; MLVWT  max
Clinical Characteristics of Patients With “Restr
Table 2 Clinical Characteristics of Patients
P
“Rest
Age, yrs
Gender: male, n (%)
Age at diagnosis, yrs
Reason for diagnosis, n (%)
Symptoms
Incidental findings
Family or gene screening
Age at onset of symptoms, yrs
Presence of symptoms (at presentation), n (%)
Dyspnea
Palpitation
Syncope
Chest pain (exertional)
NYHA functional class (at presentation), n (%)
I
II
III and IV
NYHA functional class (at last evaluation), n (%)
I
II
III and IV
Edema (by history), n (%)
Abdominal discomfort, n (%)
Exercise tolerance
Peak VO2, ml/kg/min
Peak VO2, % VO2 max
History of AF (chronic and paroxysmal), n (%)
Data shown as mean  SD or n (%). *Fisher exact test was used.
AF  atrial fibrillation or flutter; HCM  hypertrophic cardiomyopathy; NA
consumption.Mutation analysis was carried out for the 5 most common
arcomere protein gene abnormalities: beta-myosin heavy
hain (MYH7), cardiac myosin-binding protein C (MYBPC3),
ardiac troponin T (TNNT2), cardiac troponin I (TNNI3), and
lpha-tropomyosin (TPM1) genes.
ata analysis. Statistical analysis was performed using
PSS statistical software (version 10.0, SPSS Inc., Chicago,
ial Evaluation
tients at Initial Evaluation
e”
Other HCM
Patients
(n  1,207) p Value
20 6.3 (6–49) 0.001
43 8.3 (19–75) 0.001
44 6.3 (22–65) 0.09
25 6.4 (10–45) 0.001
43 9.3 (9–72) 0.001
) 1.44 0.69 (0.4–6.0) 0.001
309 182 0.001
294 (24.3%) 0.006*
HCM  hypertrophic cardiomyopathy; LV  left ventricular; LVOTO 
ft ventricular wall thickness.
Phenotype”
“Restrictive Phenotype”
ts With
Phenotype”
19)
Other HCM
Patients
(n  1,207) p Value
19 40 17 0.6
42%) 740 (61%) 0.09
20 36 17 0.5
58%) 476 (39%) 0.2
10%) 292 (24%) 0.1
32%) 307 (25%) 0.8
19 36 16 0.5
84%) 764 (63%) 0.1
63%) 422 (35%) 0.01
32%) 447 (37%) 0.4
21%) 144 (12%) 0.3*
26%) 444 (37%) 0.2
37%) 757 (63%) 0.01
47%) 389 (32%) 0.2
16%) 33 (3%) 0.02*
11%) 513 (43%) 0.00001
47%) 258 (21%) 0.1
42%) 41 (3%) 0.00001*
42%) NA NA
16%) NA NA
6.1 26.3 9.7 0.0003
15 72 21 0.00004
74%) 145 (12%) 0.00001*t Init
f Pa
ith
enotyp
)
15)
–60)
–51)
–39)
–50)
.0–4.0
–148)
ed.ictive
With
atien
rictive
(n 
42
8 (
38
11 (
2 (
6 (
38
16 (
12 (
6 (
4 (
5 (
7 (
9 (
3 (
2 (
9 (
8 (
8 (
3 (
17.3
49
14 ( not available; NYHA  New York Heart Association; VO2  oxygen
I
f
w
w
a
t
M
a
(
c
R
P
t
“
u
t
S
M
p
e
M
a
t
m
n
f
6
C
t
T
m
f
r
c
c
s
(
4
m
a
e
e
i
S
“
y
d
c
f
a
s
I
2422 Kubo et al. JACC Vol. 49, No. 25, 2007
HCM With Restrictive Phenotype June 26, 2007:2419–26llinois). All data are expressed as mean  SD (range) or
requency (percentage). Differences in continuous variables
ere assessed using Student t test. Pearson chi-square test
as used for comparisons between noncontinuous variables,
nd Fisher exact test when expected frequency was lower
han 5. Survival estimates were calculated by the Kaplan-
eier method and log-rank test. Five-year survival values
re expressed together with their 95% confidence intervals
CIs) defined as survival  1.96  SE. Statistical signifi-
ance was defined by a value of p  0.05.
esults
opulation characteristics. Nineteen patients (1.5%) from
he study cohort of 1,226 patients were classified as having
restrictive phenotype.” These 19 patients were from 16
nrelated families and included 4 patients with cardiac
roponin I mutations who had been previously reported (8).
even had MLVWT of 13 mm, and 12 patients had
LVWT of 13 to 15 mm. Eleven of the 19 patients had
roven familial HCM.
The echocardiographic characteristics of patients at initial
valuation are summarized in Table 1. The average
LVWT was 13  2.7 mm (range 7 to 15 mm). The left
trial diameter was enlarged in all of the patients studied;
he mean left atrial size was 53  4.3 mm (range 46 to 60
m). Left ventricular end-diastolic diameter was either
ormal or reduced (range 37 to 51 mm), and LV systolic
Figure 1 Changes in Rhythm Status in Patients With HCM Wit
The figure shows changes in rhythm status from the initial clinical evaluation to th
patients with hypertrophic cardiomyopathy (HCM) with “restrictive phenotype.” AF unction was preserved in all patients studied (FS: 37 
%). None showed significant mitral regurgitation.
linical significance. The clinical characteristics of pa-
ients with a “restrictive phenotype” are summarized in
able 2. The patients were age 18 years or more, and the
ajority (90%) was evaluated because of symptoms or a
amily history of HCM. At presentation, 12 patients (63%)
eported dyspnea (New York Heart Association functional
lass 2), 6 patients had palpitation, and 5 had exertional
hest pain. Cardiopulmonary exercise testing confirmed
ignificant limitation; peak VO2 was 9.0 to 28.8 ml/kg/min
mean: 17.3  6.1 ml/kg/min) (%VO2: 30% to 87%; mean,
9.3  15.1%).
During a mean follow-up period of 53.7  49.2 months,
ore patients experienced significant dyspnea (Table 2),
nd the majority (n  14, 74%) developed paroxysmal or
stablished atrial fibrillation (Fig. 1). Five patients (26%)
xperienced a significant embolic stroke, which was the
nitial presenting feature in 1 patient age 49 years.
urvival. During the follow-up period, 6 (32%) of the
restrictive phenotype” patients (age 35  9 years [21 to 45
ears]) died (sudden death in 1 patient, heart failure-related
eath in 3 patients, and stroke in 1 patient) or underwent
ardiac transplantation (n  1). Left ventricular systolic
unction and cavity dimensions were normal in all 6 patients
t the last evaluation before death. The 5-year event-free
urvival from any cause of death, cardiac transplantation, or
CD discharge was 56.4% (95% CI 29.7 to 83.2) in
trictive Phenotype
recent clinical evaluation in 19
l fibrillation; PAF  paroxysmal atrial fibrillation.h Res
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June 26, 2007:2419–26 HCM With Restrictive Phenotyperestrictive phenotype” patients versus 89.8% (95% CI 87.6
o 92.0) (log-rank p  0.008) in other HCM patients (n 
,207) (Fig. 2a). Restrictive phenotype showed a 5.23-fold
igher risk for cardiac death or transplantation or ICD
ischarge (95% CI 2.2 to 12.7, p  0.0002) when age, LV
utflow obstruction, and LVH were included in an event-
ree survival model. Postmortem examination was per-
ormed in 5 of the 6 “restrictive phenotype” patients who
ied and showed widespread myocardial disarray sufficient
o fulfill a histopathological diagnosis of HCM.
enetic results. Mutation analysis for MYH7, MYBPC3,
NNT2, TNNI3, and TPM1 genes was performed in 15 of
he 16 probands with “restrictive phenotype.” Sarcomere
ene mutations were identified in 8 probands: 4 in MYH7
nd 4 in TNNI3 (Table 3). Four of the mutations identified
ere predicted to alter restriction-enzyme sites, and this was
onfirmed by polymerase chain reaction amplification of the
elevant exons, digestion, and size fractionation on a 3%
garose gel. Mutation Arg145Trp in TNNI3 created an
ciI site, mutation Asp190Gly in TNNI3 abolished a BsrI
ite, mutation Arg453Cys in MYH7 created an NlaIII site,
nd mutation Met493Leu in MYH7 abolished an NspI site.
The mutations identified in the present study were in
unctionally important and evolutionarily conserved regions
f the genes, and they were present in all affected individuals
nd absent in at least 170 chromosomes from healthy
ndividuals. One mutation, Met493Leu, in MYH7 was
ovel. The proband (Patient #3 in Table 3) was diagnosed
s having RCM and died (from heart failure) at the age of
6 years. She did not show significant hypertrophy on
chocardiography, and her ECG indicated a low Romhilt-
stes (R-E) score (3 points). Her mother was not affected
henotypically or genotypically. Her father was not evalu-
ted because of death from a malignancy, but he had an
therwise unexplained abnormal 12-lead ECG. The pro-
and’s daughter, who carries the identical mutation
Met493Leu), was diagnosed as having HCM with mild
VH (MLVWT: 14 mm) and restrictive physiology. Her
CG showed LVH (R-E score: 6 points). The other
utations detected have been previously reported as
isease-causing (8,17).
Seven of the 8 families in whom mutations were identi-
ed had a proven family history of 1 or more affected family
embers with an unequivocal diagnosis of HCM. The
ther family (Patient #5; Family #H038 in Table 3) had no
roven HCM in the family (data not available), but 5 of the
elatives had died suddenly before the age of 50 years. Her
Patient #5) autopsy revealed extensive myocardial disarray.
The echocardiographic and Doppler findings in the
elatives of the 8 gene-positive families are shown in
able 4. There were 31 gene-positive family members
including patients with the “restrictive phenotype” [n 
]), and they exhibited variable morphological and hemo-
ynamic phenotypes (no or minimal-to-severe hypertrophy
nd with or without restrictive filling). One of the relativesFigure 2 Kaplan-Meier Curves for HCM With
Restrictive Phenotype Versus Other HCM
(A) Occurrence of all-cause mortality, cardiac transplantation, or implantable
cardioverter-defibrillator discharge during follow-up. Log-rank for trend p 
0.008. (B) Occurrence of cardiovascular death, including death from cardiac
transplantation and implantable cardioverter-defibrillator discharge, during fol-
low-up. Log-rank for trend p  0.001. (C) Occurrence of heart failure death and
cardiac transplantation during follow-up. Log-rank for trend p  0.0001. Thin
lines  restrictive phenotype; thick lines  other hypertrophic cardiomyopathy
(HCM).
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HCM With Restrictive Phenotype June 26, 2007:2419–26ad adverse LV remodeling characterized by cavity enlarge-
ent and systolic dysfunction.
iscussion
ypertrophic cardiomyopathy is a heterogeneous myocar-
ial disorder with a broad spectrum of clinical presentation
nd morphologic features (1). In this study, we identified a
istinct population with “restrictive phenotype” character-
zed by restrictive filling, minimal or no hypertrophy, and
reserved LV systolic function in our HCM cohort, al-
hough they were relatively few (1.5% of patients from 2.3%
f families). The fact that they had a family history of
CM, typical histology at explant or post mortem, and/or a
utation in beta-myosin heavy chain or cardiac troponin I
upports the view that these patients form part of the
ncreasingly diverse spectrum of HCM. Clinical presenta-
ion with RCM is uncommon in clinical practice. It is
ncertain how often such a presentation is a manifestation
f HCM, but our data support such consideration with the
nherent clinical implications, perhaps the most important
eing the need for familial evaluation.
enotype/phenotype relations. In patients with the “re-
trictive phenotype,” 6 different mutations were identified in
probands in MYH7 and TNNI3 genes. Five of these
utations have previously been described as disease-
ausing: 2 in MYH7 (Arg453Cys, Val606Met) and 3 in
NNI3 (Leu144Gln, Arg145Trp, Asp190Gly) (8,17). One
utation in MYH7 (Met493Leu) was novel and localized
ithin an important domain (the relay-helix domain; amino
esults of Genotyping in Probands With “Restrictive Phenotype”
Table 3 Results of Genotyping in Probands With “Restrictive P
Patient
No.
Family
No. Gender
Age at
Presentation (yrs) Sarcomere Gene
1 H154 F 34 MYH7
2 H561 F 28 MYH7
3 H625 F 45 MYH7
4 H260 M 24 MYH7
5 H038 F 27 TNNI3
6 H805 F 67 TNNI3
7 H816 M 70 TNNI3
8 H640 F 25 TNNI3
SH  asymmetrical septal hypertrophy; CHF  congestive heart failure; LVH  left ventricular hy
s in Table 1.
Echocardiographic/Doppler Findings in 31 Fami
Table 4 Echocardiographic/Doppler Finding
Restrictive Filling
Pattern (<12 mm)
Absent (n  19) 14 (9*: normal ECG)
(5: abnormal ECG)
Present (n  3  9†) 4†
*Of 9 members who were phenotypically negative, 6 were age16 yea
“restrictive phenotype” in Table 3 and 1 patient (a daughter of Patient #
systolic function (fractional shortening  10%).
ECG  electrocardiogram; MLVWT  maximum left ventricular wall thickncid residues from numbers 479 to 512) of MYH7 that has
een strictly conserved throughout evolution. To date, only
utations in TNNI3 have been associated with “restrictive
henotype” in HCM. In this study, we identified for the
rst time MYH7 mutations associated with HCM charac-
erized by “restrictive phenotype.” The fact that no muta-
ions were found in MYBPC3, the most common HCM
isease-causing gene, is of interest, particularly as MYBPC3
utations appear to cause all of the recognized disease
anifestations (18).
How these mutations result in the “restrictive phenotype”
as not been systematically evaluated and remains specula-
ive. For TNNI3 mutations, previous expression studies in
CM revealed increased calcium sensitivity and diminished
nhibition of the actomyosin ATPase activity (19,20). The
earts of TNNI3 transgenic mice showed increased contrac-
ility and impaired relaxation (21). Similarly, analyses of
uscle mechanics in cardiac myocytes from mice that were
ngineered to contain a human hypertrophic myosin mis-
ense mutation demonstrated increased actin-activated
TPase activity, greater force production, and faster actin-
lament sliding (22). The observation of an increase in fiber
tiffness under relaxing conditions with a MYH7 mutation
n human slow skeletal muscle has also been reported (23).
hese findings may influence the development of the
restrictive phenotype.” The fact, however, that not all
atients from the same family develop the “restrictive
henotype” suggests that other genetic and/or environmen-
al factors are involved and again underscores the genetic/
henotypic heterogeneity of HCM (2).
type”
Mutation
Proven
Familial HCM
LVH on
Echocardiography
and MLVWT (mm)
Status
(Event, Age [yrs])
Arg453Cys  15 mm concentric Died (stroke, 38)
Arg453Cys  14 mm concentric Transplant, 31
Met493Leu  11 mm Died (CHF, 45)
Val606Met  15 mm ASH Alive
Leu144Gln  13 mm ASH Died (CHF, 30)
Arg145Trp  9 mm Alive
Arg145Trp  11 mm Alive
Asp190Gly  10 mm Alive
hy; MYH7  beta-myosin heavy chain gene; TNNI3  cardiac troponin I gene; other abbreviations
mbers Who Carried a Mutation
1 Family Members Who Carried a Mutation
MLVWT
to 15 mm) (16 to 29 mm) (30 mm <)
0 4 1
5† 3‡ 0
3 were between 20 and 40 years of age; †these 9 were probands with
le 3 asmentioned in the text); ‡1 of them had reduced left ventricularhenoly Me
s in 3
(13
rs and
3 in Tabess.
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June 26, 2007:2419–26 HCM With Restrictive Phenotypelinical significance of restrictive phenotype. Patients
ith the “restrictive phenotype” were significantly more
imited both subjectively and on cardiopulmonary exercise
esting (16). The explanation for the observed exercise
mpairment relates to the severe diastolic dysfunction. In
revious studies, diastolic dysfunction appeared to be one of
he most important determinants of exercise capacity in
atients with HCM (5–7). These studies have suggested
hat impairment of diastolic filling with increasing heart rate
imits stroke volume augmentation during exercise.
Hypertrophic cardiomyopathy is generally associated
ith mild disability and normal life expectancy if sudden
eath can be prevented (24–26). Patients with the “restric-
ive phenotype,” however, had an extremely poor prognosis
ith an overall survival rate of 56% at 5 years, more closely
esembling the poor prognosis of patients with idiopathic
CM (27–29). The main cause of death in “restrictive
henotype” patients was related to heart failure: 42% devel-
ped signs of right heart failure, including edema, abdom-
nal discomfort, and ascites. “Restrictive phenotype” pa-
ients were also more prone to atrial fibrillation/flutter and
troke, presumably as a consequence of elevated filling
ressure and left atrial enlargement (30,31). In general,
aintenance of sinus rhythm to avoid loss of atrial contri-
ution to ventricular filling and to reduce embolic risk is
esirable, but this may be difficult to achieve in HCM with
restrictive phenotype” given the marked atrial enlargement
nd rapid progression of right heart failure. The threshold
o anticoagulate should, therefore, be low given the signif-
cant stroke risk, 26% in this study.
tudy limitations. In the present study, we used only
itral flow Doppler indexes to clarify restrictive and non-
estrictive patients because many examinations were per-
ormed before tissue Doppler study became available. A
ore complete analysis of the diastolic function by using
issue Doppler measurements such as diastolic mitral annu-
us velocities would be desirable in future studies to appro-
riately assess restrictive physiology.
In this study, although we cannot exclude the possibility
hat some patients are part of late-stage HCM that leads
ither to “dilated-hypokinetic” HCM with a dilated LV and
ystolic impairment, or to “restrictive form” HCM with
rogressive biatrial dilatation and a restrictive filling pattern
f mitral inflow, none of the patients with “restrictive
henotype” was documented in the clinical course of pro-
ressive LV remodeling (32–34). Therefore, those patients
ere considered to present restrictive phenotype resembling
CM as initial manifestation.
We performed genetic screening in 5 sarcomere genes.
ther genes, such as cardiac actin, essential myosin light
hain, and regulatory myosin light chain, were not analyzed
n the “restrictive phenotype” patients. In addition, we did
ot investigate modifier factors (polymorphisms in the gene
ncoding renin-angiotensin-aldosterone proteins, for in-
tance) that may contribute to the phenotypic expression.
1onclusions
he “restrictive phenotype” characterized by minimal or no
ypertrophy with restrictive filling is part of the clinical
pectrum of HCM and is associated with severe limitation,
iastolic heart failure, and high rates of atrial fibrillation/
utter and stroke. This phenotype seems to be related to
utations in beta-myosin heavy chain and cardiac troponin I.
rognosis is poor, and patients may ultimately require cardiac
ransplantation.
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